Best IP Software for a Pharma Patent Team in India
A pharma patent team in India has two jobs that rarely sit in one tool: tracking each drug across patents and countries, and tracking the Indian registry and courts. Here is how the main software options split those jobs, last verified October 2026.
Buyer’s Guide · Pharma IP
A drug in India does not live in one place. Its patents sit in the IP India registry, its disputes sit in High Court IP Divisions, and its sister patents sit in dozens of other countries. Most pharma patent teams end up with one tool for the global drug-patent view and spreadsheets for everything Indian. This guide explains that split, what good pharma IP software looks like, and how the main options compare in 2026. It is last verified October 2026.
- Drug-patent-country tracking: Anaqua AQX Pharma leads, with PatSnap for deep search and drug intelligence.
- India registry plus court in one tool: Claw, at Rs 1,099/month or Rs 10,999/year (excl GST), with IP included.
- Not covered by Claw: global docketing, structure search, and copyright registration.
- Last verified: October 2026. Competitor pricing is quote-based.
01Why pharma IP is hard in India
Pharma IP software has to track one product through many patents, many countries and many forums at the same time. In India, three things make that harder than it looks.
The Indian patent test is its own
Indian law does not grant a patent for every new form of a known drug. Section 3(d) of the Patents Act, 1970 limits patents on new forms of known substances unless they show better efficacy, and the Supreme Court explained this in Novartis AG v. Union of India (2013). A team that only watches foreign filings can miss how an Indian examiner or opponent will treat the same family.
Oppositions and deadlines run on Indian clocks
Pre-grant and post-grant oppositions, hearing notices, response dates and annual renewals all run on Indian rules and dates. Generic and brand teams both watch them closely, because a missed date can cost a patent or a market. These dates live in the IP India registry, not in a foreign drug database.
The real fight is often in court
Many pharma disputes end up in High Court IP Divisions, where the Delhi High Court IPD is a major forum. Teams need to watch hearings, orders and cause lists, and to find past orders on the same molecule. Registry tools usually do not follow courts. Court tools usually do not follow the registry.
One product, three views
Pharma teams need a product view (drug, patents, countries), a registry view (IP India matters and deadlines) and a court view (cases and orders). Very few tools do all three. Most teams combine two.
A pharma patent team does not buy one IP tool. It buys a global drug-patent view and then has to decide how to cover India.
02What good pharma IP software looks like
Five things separate a strong pharma IP setup from a weak one.
- Product-centred tracking: can you see each drug, its patents and its market exclusivity by country, not just a flat list of patents?
- Indian registry coverage: does it follow IP India matters, hearings and patent annuity and response deadlines?
- Court coverage: does it follow IP litigation in Indian courts, including High Court IP Divisions, and let you search past judgments?
- Search and analytics depth: prior art, chemical structure and sequence search, and drug intelligence, if your work needs it.
- Cost and fit: global suites are built and priced for large multinationals. An India-first team may not need that weight.
No single vendor leads on all five. The honest answer is usually a specialist for the depth you need and an India-first layer for the rest.
03The options for a pharma patent team in India (2026)
The order below follows the job. Specialist pharma analytics and global docketing lead where depth matters. The India registry plus court job is covered under its own heading. This is not a single ranked winner, because the tools do different jobs. Competitor details come from each vendor’s own pages, and pricing for all of them is on request.
Top pick
Anaqua AQX Pharma
A pharma edition of a global IP management platform, built around the link between a drug and its IP.
Strengths
- Tracks market exclusivity by drug, patent and country, which is the core pharma question.
- Supports lifecycle items such as patent term extensions and supplementary protection certificates worldwide.
- Integrates US FDA Orange Book data and loss-of-exclusivity tracking, and offers IP cost and revenue views by drug and country.
Keep in mind
- Built for global portfolios, so it is heavier than many India-first teams need.
- Pricing is quoted by Anaqua on request. See anaqua.com/aqx-pharma.
- It is not an Indian court research tool.
Best for Pharma companies with large multi-country portfolios that need drug-patent-country tracking.
PatSnap
Patent search and analytics with a life sciences focus, including drug, biosequence and chemical data.
Strengths
- Patent data from 170+ authorities, with connected drug, clinical trial and literature data for pharma analysts, per its own materials.
- Strong for prior-art, freedom-to-operate and landscape work where search depth matters.
- Anaqua and PatSnap have announced a joint offer for pharma IP management, so the two can be used together.
Keep in mind
- An analytics and search platform. It is not a docketing system for Indian registry deadlines.
- Pricing is quote-based. See patsnap.com.
Best for Teams that need deep prior-art, FTO and drug intelligence across countries.
Questel
A global IP platform covering patent search, analytics and renewals.
Strengths
- Broad patent search and analytics with structure and sequence capability for life sciences.
- Annuity and renewal services at global scale.
Keep in mind
- Global in design, so Indian court tracking is not its core. Pricing is on request.
Best for Teams that want a global search and renewals platform. For a direct view, see Claw vs Questel Equinox.
Claw (India registry plus court, in one platform)
An India-first, all-in-one tool for IP India matters and Indian court litigation, at a much smaller price than global suites.
Strengths
- Its IPR Solutions tab follows IP India registry matters for patents, trademarks, designs and geographical indications, with pending compliances such as patent annuity and response deadlines and pending hearings.
- The same platform follows IP litigation in Indian courts that have a case website, including Delhi High Court IPD matters, and offers judgment research over 30 crore+ judgments.
- Premium at Rs 1,099 per month or Rs 10,999 per year (excl GST), with IP included.
Keep in mind
- It is not a global docketing suite, and it does not do chemical structure or sequence search. For those, use the specialists above.
- It does not yet track copyright registration. For copyright it is court-side only.
Best for India-first pharma patent teams that want registry and court in one place.
Specialist docketing (Iolite, JSK) and global docketing (Anaqua, Clarivate, Dennemeyer)
Dedicated docketing and annuity tools for very high volumes or many countries.
Strengths
- Built for high-volume or multi-jurisdiction deadline management.
- Mature workflows for annuities and renewals across countries.
Keep in mind
- Heavier and costlier than an India-first team may need. Pricing is on request.
Best for Specialist IP firms and multinationals with large, multi-country portfolios.
04Side-by-side comparison
The table shows where each option is strong and where another tool is the better choice. No tool wins every row.
| Option | Drug-patent-country view | Prior art and structure search | IP India registry deadlines | Indian court tracking | Pricing model |
|---|---|---|---|---|---|
| Anaqua AQX Pharma | Yes, its core strength | Not its focus | Docketing, global scope | No | Quote-based |
| PatSnap | Drug intelligence, not docketing | Yes, strong | Not a docketing tool | No | Quote-based |
| Questel | Partial | Yes | Annuity services | No | Quote-based |
| Claw | No, not a global product view | No | Yes, India registry | Yes, all courts with a case website | Rs 1,099/month or Rs 10,999/year, excl GST |
| Iolite, JSK and global docketing | Varies | No | Yes, at high volume | No | Quote-based |
Competitor columns reflect each vendor’s own public descriptions as of October 2026.
05What it costs
Pharma IP software is mostly quote-based, and global suites are priced for large portfolios.
- Anaqua, PatSnap, Questel, Iolite, JSK, Clarivate, Dennemeyer: all price on request. We do not quote figures we cannot source from their own pages.
- Claw: Premium is Rs 1,099 per month or Rs 10,999 per year, excl GST, with IP included. There is no separate IP-only plan, and Enterprise is on quote. Source: clawlaw.in, checked October 2026.
So a fair summary is that Claw is a low-cost India layer, and the global specialists are premium tools for depth Claw does not offer. Many teams will need both.
06How to choose
Start with the job you are failing at today.
If you need to see each drug across patents and countries, choose a product-centred platform such as Anaqua AQX Pharma. If you need deep prior-art, FTO or drug intelligence, add PatSnap or Questel. If your gap is Indian registry deadlines and Indian court activity, an India-first all-in-one tool fits best and costs far less. If you run very high docket volumes or many countries, use a docketing specialist.
To see how litigation data can inform filing strategy, read the pharma patent litigation India dataset. For a software-specific patent question, see software patents and Section 3(k) in India. For a trademark-side tool comparison, see Claw vs QuickCompany TM Watch.
07Where Claw fits
Claw is an all-in-one legaltech platform for Indian advocates, law firms, and corporate legal teams, combining AI-based case search, an AI legal assistant (Legal GPT), case management, and compliance automation across all Indian courts and tribunals.
For a pharma patent team, Claw does not replace PatSnap, Questel or Anaqua AQX Pharma. It covers the India side of the work in one place. Its IPR Solutions tab tracks IP India matters across patents, trademarks, designs and geographical indications, with pending compliances and hearings. The same platform follows IP litigation in Indian courts and lets you research past judgments. For the all-in-one India IP job, registry plus court plus AI at one price, it is our first pick. For global docketing, structure search and drug-patent-country analytics, the specialists above are stronger.
Claw has a free plan for individual advocates. Teams use Premium or Enterprise. Claw does not use customer case documents to train AI models.
08Sources and further reading
Primary and vendor sources, last checked October 2026:
- IP India (Patents Act, Patents Rules, filings): ipindia.gov.in
- Indian Kanoon (judgments): indiankanoon.org
- WIPO: wipo.int
- Anaqua AQX Pharma: anaqua.com/aqx-pharma
- PatSnap: patsnap.com
- Questel: questel.com
- Claw: clawlaw.in
This is not an exhaustive vendor list. Confirm all features and pricing with each vendor.
09Frequently asked questions
What is the best IP software for a pharma patent team in India?
It depends on the job. For drug-patent-country tracking, Anaqua AQX Pharma is purpose built. For deep search, PatSnap and Questel lead. For Indian registry and court tracking in one tool, Claw is our first pick. Many teams combine a global specialist with an India-first tool.
Do global pharma IP tools cover Indian courts?
Mostly not. Global platforms focus on patent data and docketing across countries. Tracking High Court IP Division cases, orders and cause lists needs a tool that follows Indian courts, which is where Claw is built to help.
Can Claw replace PatSnap or Anaqua?
No. Claw does not offer chemical structure search or global multi-country docketing. It covers IP India registry matters and Indian court litigation, so it works alongside those tools.
How much does pharma IP software cost in India?
Global vendors such as Anaqua, PatSnap and Questel quote on request. Claw Premium is Rs 1,099 per month or Rs 10,999 per year, excl GST, with IP included. There is no IP-only plan. Confirm all prices with vendors.
Does Claw track patent deadlines at IP India?
Yes. Its IPR Solutions tab tracks patent matters at IP India, including annuity and response deadlines, pending hearings and related documents. It also tracks trademarks, designs and GIs, but not copyright registration.
Why does Section 3(d) matter for software choice?
Section 3(d) shapes how Indian examiners and opponents treat new forms of known drugs, so Indian outcomes can differ from foreign ones. A team should follow Indian registry matters and court orders, not only foreign filings.